Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (8385)	1/19/1999 8:21:00 PM
From: William L. Molair II	Respond to of 17367

Has anyone been able to contact Ellen lately? I tried once late last week and again today. Left messages both times. In the past, she has always been very quick to call back. Maybe she is checking out Bermuda? (more than likely, she is busy doing her job and hasn't had a spare moment to call me back)

To: Tharos who wrote (8385)	1/19/1999 9:21:00 PM
From: aknahow	Respond to of 17367

Cantab is in the news. Will post if I can find it again. Note Cantab has licensed a cell expression process from XOMA. "A proprietary bacterial cell expression system for high-yield manufacturing of recombinant proteins for pharmaceuticals licensed to many biopharmaceutical companies, including Affymax Research Institute, Cantab Pharmaceuticals Research Ltd, Eli Lilly and Company, Enzon, Inc., the Hoechst Group, ICOS Corporation, Pasteur Mérieux Serums & Vaccins, and the Pharmacia & Upjohn Group of companies." Here is the CANTAB news. Does XOMA have any involvement? Don't know but if anyone is calling XOMA, please ask. Cantab Reports on Amelioration of Inflammatory Bowel Disease with OX40-IgG Fusion Protein - Preclinical Work on New Treatment Approach Published in Journal of Immunology - CAMBRIDGE, England, Jan. 19 /PRNewswire/ -- Cantab Pharmaceuticals plc (Nasdaq: CNTBY; LSE: CTB) today announced the publication of a preclinical study in the Journal of Immunology (January issue) describing a promising new approach to the treatment of inflammatory bowel disease. The paper, entitled ''Regulation of T Cell Activation in vitro and in vivo by Targeting the OX40-OX40 Ligand Interaction: Amelioration of Ongoing Inflammatory Bowel Disease with an OX40 IgG Fusion Protein,'' highlights the crucial role of a highly specific protein-protein interaction relating to T cell activation, a key cell type responsible for orchestrating the human immune response. This study was undertaken by a team of scientists from St. Bartholomew's Hospital, London, and Cantab. The cell surface receptor protein, OX40, is a member of the tumor necrosis factor receptor superfamily which, along with their corresponding ligands, are responsible for a range of functions including the proliferation, activation and death of cells. The therapeutic potential of targeting OX40 lies in its limited cellular expression, predominately on activated CD4 T cells which are believed to be central to the pathogenesis of a range of human diseases including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and graft-versus-host disease. Based on their understanding of the intricate mechanisms involved in T cell activation through OX40, Cantab scientists have developed an OX40-IgG fusion protein that is capable of blocking T cell proliferation and cytokine production. In the Journal of Immunology study, Tom MacDonald, Ph.D., and his colleagues at St. Bartholomew's Hospital demonstrated the ability of the OX40-IgG fusion protein to ameliorate T cell-mediated colitis in two mouse models of inflammatory bowel disease.